piroxicam-beta-cyclodextrin: drug combination consisting of beta-cyclodextrin & piroxicam; RN given refers to unknown ratio [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 54697648 |
| SCHEMBL ID | 123958 |
| SCHEMBL ID | 1649802 |
| MeSH ID | M0169417 |
| Synonym |
|---|
| chf 1194 |
| chf-1194 |
| piroxicam-beta-cyclodextrin |
| 96684-39-8 |
| SCHEMBL123958 |
| SCHEMBL1649802 |
| piroxicambeta-cyclodextrin |
| 121696-62-6 |
| DTXSID60242388 |
| piroxicam-|a-cyclodextrin(x:1) |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Although NSAIDs are very effective drugs, their use is associated with a broad spectrum of adverse reactions in the liver, kidney, cardiovascular (CV) system, skin and gut." | ( Piroxicam-β-cyclodextrin: a GI safer piroxicam. Scarpignato, C, 2013) | 0.39 |
Piroxicam-beta-cyclodextrin (PBC) was developed with the aim of improving the hydrosolubility and bioavailability of piroXicam. As the inclusion complex of PBC is more water soluble, the absorption rate of the drug is increased.
| Excerpt | Reference | Relevance |
|---|---|---|
| " As the inclusion complex of piroxicam-beta-cyclodextrin is wettable and more water soluble, the absorption rate of the drug is increased whilst its other pharmacokinetic characteristics remain unchanged." | ( Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions. Acerbi, D; Allemon, AM; Deroubaix, X; Lebacq, E; Stockis, A; Ventura, P, 1995) | 0.58 |
| " The absorption rate of piroxicam from the complex, determined using tmax, absorption rate constant (Ka) and plasma concentrations at 15 min and 30 min post-dose, is considerably faster than that for plain piroxicam." | ( Supermolecular inclusion of piroxicam with beta-cyclodextrin: pharmacokinetic properties in man. Acerbi, D; Merz, PG; Rietbrock, N; Rietbrock, S; Woodcock, BG, 1993) | 0.29 |
| "Piroxicam-beta-cyclodextrin (PBC), a complex of piroxicam with beta-cyclodextrin, was developed with the aim of improving the hydrosolubility and bioavailability of piroxicam." | ( Effects of piroxicam-beta-cyclodextrin on the gastrointestinal tract. Warrington, S, 1993) | 2.12 |
| " This results in an increase in the rate of absorption of the active compound and, consequently, in an earlier onset of analgesic action." | ( Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease. Franchimont, P; Reginster, JY, 1993) | 1.73 |
| " Bioavailability of piroxicam in plasma is higher after treatment with the inclusion product than with free piroxicam." | ( Pharmacokinetic profile of piroxicam beta-cyclodextrin, in rat plasma and lymph. Bersani-Amado, CA; Kimura, E; Oga, S; Santos, SR; Sudo, LS, 1997) | 0.3 |
| " Piroxicam-beta-cyclodextrin (PBCD) was developed for pain indication by virtue of the increased absorption rate of piroxicam." | ( Comparative population pharmacokinetic-pharmacodynamic analysis for piroxicam-beta-cyclodextrin and piroxicam. Hu, C; Miller, R; Wang, D; Zheng, J, 2000) | 1.45 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gastroscopy was performed at base-line and after the dosing period of 14 days." | ( [Comparative endoscopic study of gastroduodenal tolerance of piroxicam-beta-cyclodextrin vs piroxicam]. Müller, P; Simon, B, ) | 0.37 |
| "These results suggest that the newly developed dosage form of piroxicam is effective and well tolerated in the treatment of patients with chronic BP." | ( Efficacy and tolerability of piroxicam-beta-cyclodextrin in the outpatient management of chronic back pain. Buran, I; Gazdik, F; Gogolak, I; Mihal, A; Pijak, MR; Turcani, P; Turcaniova, Z, 2002) | 0.61 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 14 (53.85) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (57.81) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 15 (51.72%) | 5.53% |
| Reviews | 5 (17.24%) | 6.00% |
| Case Studies | 1 (3.45%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (27.59%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preemptive Use of Piroxicam-beta-Cyclodextrin on Tooth Sensitivity Caused by In-office Bleaching: Randomized, Triple-blind, Controlled Clinical Trial [NCT03153657] | Phase 3 | 50 participants (Anticipated) | Interventional | 2016-12-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||